Ondine Biomedical Inc. (AIM:OBI)

Market Cap	46.56M
Revenue (ttm)	1.14M
Net Income (ttm)	-10.60M
Shares Out	443.43M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,929
Average Volume	128,067
Open	10.95
Previous Close	10.50
Day's Range	10.00 - 10.95
52-Week Range	5.50 - 13.30
Beta	0.12
RSI	64.53
Earnings Date	Sep 25, 2025

About Ondine Biomedical

Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of treat infections, including those caused by drug-resistant pathogens antimicrobial therapies in Canada and internationally. Its main product Steriwave, enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers pipeline products on platform which includes burns, ventilator tube, and sinus; and Serious, Chronic wounds, Chronic sinusitis, Ventilator-associated pneumonia VAP, Central lin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 18
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: OBI

Financial Performance

In 2024, Ondine Biomedical's revenue was 2.05 million, an increase of 70.32% compared to the previous year's 1.20 million. Losses were -19.10 million, 32.5% more than in 2023.

Financial numbers in CAD